Company Overview of Oxford Gene Technology IP Limited
Oxford Gene Technology IP Limited provides genetics research and biomarker solutions to advance molecular medicine worldwide. Its products include CytoSure international standards for cytogenomic arrays; CytoSure ISCA UPD arrays that allow the detection of DNA copy number variation with whole chromosome uniparental disomy; CytoSure ISCA UPD arrays that combines long oligo aCGH probes for copy number variation detection; and CytoSure Syndrome Plus v2 arrays for the detection of DNA aberrations across the genome. The company's products also comprise Aneuploidy arrays for the simplified detection of chromosome imbalances; CytoSure single cell aneuploidy arrays to detect aneuploidies when workin...
Begbroke Science Park
Begbroke, OX5 1PF
Founded in 1995
Key Executives for Oxford Gene Technology IP Limited
Founder, Chairman of The Board and Chief Science Advisor
Executive Vice President of R&D
Executive Vice President of Commercial
Compensation as of Fiscal Year 2015.
Oxford Gene Technology IP Limited Key Developments
Oxford Gene Technology Launches New Arrays for Developmental Disorders at European Society of Human Genetics
Jun 8 15
Oxford Gene Technology (OGT) launching a new range of arrays at the European Society of Human Genetics (ESHG) Conference in Glasgow, UK, that are dedicated to elucidating the underlying causes of developmental delay. OGT’s unique Cytosure Constitutional v3 arrays have been developed following its recent licence agreement with the Wellcome Trust Sanger Institute to access the Deciphering Developmental Disorders (DDD) study data which successfully identified new areas of the genome responsible for developmental disorders. 1, 2 OGT has used this data, together with the latest updates from ClinGen, to deliver the most advanced, high-resolution developmental disorder arrays currently available. OGT has optimised the arrays through a proprietary probe design algorithm and experimental validation, enabling the selection of highly-targeted, specific probes throughout the genome. Using an informed, sophisticated approach to array design, more of these optimised probes have been placed in regions of the genome that are most likely to detect a biologically relevant aberration. The result of this careful design procedure means that regions with the high priority are covered at exon-level resolution on the arrays, enabling single-exon CNV detection in up to 502 prioritized genes of interest. Providing straightforward analysis, all CytoSure arrays come with OGT’s renowned Cytosure Interpret Software and full on-site training, streamlining data analysis and interpretation. Innovative features enable the automation of data analysis workflows, minimizing user intervention and maximizing both consistency and speed of interpretation.
Oxford Gene Technology Gets £1.2 Million Genomics England Contract
Mar 11 15
Oxford Gene Technology (OGT) announced that it has been awarded a £1.2 million phase two Small Business Research Initiative (SBRI) Healthcarecontract. The contract is to develop Next Generation Sequencing (NGS) analysis software, following the successful completion of phase one and an evaluation by Genomics England, UK Department of Health and Innovate UK. Development of this innovative technology will increase the accuracy and ease of interpreting whole genome genetic variant data by clinicians, supporting more precise treatment decisions. In addition to the analysis of NGS data, the software will integrate a full spectrum of genetic tests, including NGS, Sanger sequencing, microarray and fluorescence in situ hybridisation (FISH). The results of these tests will be put in context via the use of both public and private databases, providing the clinician with prioritised clinically relevant results. These easy to understand reports will support faster diagnosis and better patient care.
Oxford Gene Technology IP Limited Announces Revenue Results for the Year Ended September 30, 2014
Dec 2 14
Oxford Gene Technology IP Limited announced revenue results for the year ended September 30, 2014. For the period, the company reported total revenue grew by 27% to £15.2 million against £11.9 million a year ago.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|